-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$16.7532.73% Upside
Perspective Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Perspective Therapeutics, Inc.?
Perspective Therapeutics, Inc. has been rated by research analysts at Truist Financial, Bank of America Securities, Oppenheimer, RBC Capital in the past 90 days.